Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 3—March 2011
Research

Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008

Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla, Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. ShinComments to Author 
Author affiliations: Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (G.E. Velásquez, S. Atwood, S.S. Shin); Instituto Nacional de Salud, Lima, Peru (M. Yagui, L. Asencios); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.P. Cegielski); Socios En Salud, Lima (J. Bayona, C.C. Conteras, S.S. Shin); Partners In Health, Boston (S.S. Shin); Dartmouth College, Hanover, New Hampshire, USA (J. Bayona); Ministerio de Salud del Perú, Lima (C. Bonilla, H.O. Jave); Dirección de Salud V Lima Ciudad, Lima (G. Yale); Dirección de Salud IV Lima Este, Lima (C. Suárez)

Main Article

Table 3

Prevalence estimates of TB drug resistance from national and regional surveillance data, and proportion of drug resistance in study cohort, Lima, Peru, 2005–2008*

Cohort Total no. patients No. (%) susceptible to INH and RIF No. (%) monoresistant to INH or RIF No. (%)
MDR TB
Peruvian NTP drug-resistance surveillance, national data (21)
All TB patients 2,167 1,829 (84.4) 158 (7.3) 180 (8.3)
New TB patients 1,816 1,597 (87.9) 124 (6.8) 95 (5.2)
Previously treated patients
351
232 (66.1)
34 (9.7)
85 (24.2)
Peruvian NTP drug-resistance surveillance, regional data corresponding to study area†
All TB patients 580 467 (80.5) 41 (7.1) 72 (12.4)
New TB patients 476 396 (83.2) 33 (6.9) 47 (9.9)
Previously treated patients
104
71 (68.3)
8 (7.7)
25 (24.0)
Study cohort
All TB patients 1,241 661 (53.3) 161 (13.0) 419 (33.8)
New TB patients 612 333 (54.4) 84 (13.7) 195 (31.9)
Previously treated patients
629
328 (52.2)
77 (12.2)
224 (35.6)
Study cohort, smear-positive samples only
All TB patients 1,114 581 (52.2) 143 (12.8) 390 (35.0)
New TB patients 531 278 (52.4) 73 (13.8) 180 (33.9)
Previously treated patients 583 303 (52.0) 70 (12.0) 210 (36.0)

*TB, tuberculosis; INH, isoniazid; RIF, rifampin; MDR, multidrug resistant; NTP, National Tuberculosis Control Program.
†Ministerio de Salud, Peru, unpub. data.

Main Article

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external